Positive News for TCR2 Therapeutics – The U.S. FDA Granted Orphan Drug Designation to Gavo-Cel for Cholangiocarcinoma

TCR2 Therapeutics
TCR2 Therapeutics (TCRR) is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from cancer. TCR2’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA).

In . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.